Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
Marta Baviera, Andreana Foresta, Pierluca Colacioppo, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
Chia‐Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 14
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Giovanna Gallo, Massimo Volpe
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2484-2484
Open Access | Times Cited: 10
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study
Fei‐Yuan Hsiao, Elise Tan, Lin-Chieh Meng, et al.
The Lancet Healthy Longevity (2024), pp. 100621-100621
Open Access | Times Cited: 6
Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
Filippo Trombara, Nicola Cosentino, Alice Bonomi, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
Jincheng Shen, Amara Sarwal, Ravinder Singh, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta‐analysis
Zijing Zhou, Min Zheng, Zhihong Zuo, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 3, pp. 1647-1656
Open Access | Times Cited: 3
SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation
Yi‐Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 3
Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes
Melissa R. Riester, Andrew R. Zullo, Richa Joshi, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3403-3417
Closed Access | Times Cited: 2
A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?
Fabrice Bonnet, Mark E. Cooper, Laetitia Koppe, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 55-65
Open Access | Times Cited: 2
Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 10, pp. 100135-100135
Open Access | Times Cited: 6
Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence
Sanket Seksaria, Bhaskar Jyoti Dutta, Mandeep Kaur, et al.
Current Diabetes Reviews (2023) Vol. 20, Iss. 6
Closed Access | Times Cited: 5
Early use of SGLT2 inhibitors reduces the progression of diabetic kidney disease: a retrospective cohort study
Shaowei Pang, Xiaoli Li
American Journal of Translational Research (2024) Vol. 16, Iss. 9, pp. 4967-4978
Closed Access | Times Cited: 1
Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review
Salman Tariq, M. Ali, Haris Iftikhar, et al.
Cureus (2024)
Open Access | Times Cited: 1
The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials
Yi Zhou, Feng‐Rong Wang, Feifei Wen, et al.
Acta Cardiologica (2023) Vol. 79, Iss. 3, pp. 274-283
Closed Access | Times Cited: 3
ІНСУЛІНОРЕЗИСТЕНТНІСТЬ ТА ГІПЕРГЛІКЕМІЯ – ОСНОВНІ ПРЕДИКТОРИ УСКЛАДНЕНОГО ПЕРЕБІГУ ГОСТРОГО ІНФАРКТУ МІОКАРДА У ХВОРИХ ІЗ КОМОРБІДНИМ МЕТАБОЛІЧНИМ СИНДРОМОМ ТА ЦУКРОВИМ ДІАБЕТОМ 2-ГО ТИПУ
М. І. Швед, І. О. Ястремська, Р. М. Овсійчук
Здобутки клінічної і експериментальної медицини (2023), Iss. 4, pp. 42-52
Open Access | Times Cited: 2
CORRECTION OF CHANGES IN LIPID METABOLISM AND REDOX SYSTEM IN PATIENTS WITH STEMI IN THE SETTING OF INSULIN RESISTANCE
М. І. Швед, I.O. Yastremska, R.M. Ovsiichuk
Art of Medicine (2023), pp. 77-82
Open Access | Times Cited: 2
The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
Zhiyuan Cheng, Shuang Wang, Fu‐Rong Li, et al.
Journal of Diabetes (2024) Vol. 16, Iss. 10
Open Access
Current Selective Drugs
Mukesh Nandave
(2024), pp. 439-499
Closed Access
The Action of Colchicine in Patients with Metabolic Syndrome and Obesity: Perspectives and Challenges
Fábio Vieira de Bulhões, Gabriele Eliza Assis, Ana Beatriz Cazé, et al.
Metabolites (2024) Vol. 14, Iss. 11, pp. 629-629
Open Access
Glucagon-Like Peptide-1 Receptor Agonists: Best Choice for Patients With Cirrhosis and Diabetes?
Yuanyuan Li, Xiaoze Wang
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 5, pp. 1142-1143
Closed Access | Times Cited: 1
Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100179-100179
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top